H1 2026 saw 5% net sales growth at constant currencies, driven by biosimilars, which now make up 33% of sales. Core EBITDA margin expanded to 20.9%, and North America led with 47% biosimilar growth. Full-year guidance for sales and margin expansion is confirmed.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.